Citalopram as an adjuvant in chronic schizophrenia: A double-blind placebo-controlled study

Acta Psychiatrica Scandinavica

Volumn 94, Issue 3, 1996, Pages 175-180

  Salokangas, R K R ^a,b   Saarijarvi S ^a   Taiminen, T ^a   Kallioniemi, H ^b   Lehto, H ^b   Niemi, H ^a   Tuominen, J ^b   Ahola, V ^b   Syvalahti E ^b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Antidepressants; Citalopram; Neuroleptics; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CITALOPRAM; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PLACEBO; THIORIDAZINE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; WELLBEING;

EID: 0029809081     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1996.tb09844.x     Document Type: Article

References (41)

1. SNYDER SH. The dopamine hypothesis of schizophrenia; focus on the dopamine receptor. Am J Psychiatry 1976: 133: 197-202.
2. WADDINGTON JL. Schizophrenia: developmental neuroscience and pathobiology. Lancet 1993: 341: 531-538.
3. ANDREASSEN NC, OLSSEN S. Negative versus positive schizophrenia. Arch Gen Psychiatry 1982: 39: 789-794.
4. MCGLASHAN TH, CARPENTER WT. Postpsychotic depression in schizophrenia. Arch Gen Psychiatry 1976: 33: 231-239.
5. BREIER A, SCHREIBER JL, DYER J, PICKAR D. National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry 1991: 48: 239-246.
6. DELISI L, NECKERS L, WEINBERGER D, WYATT RJ. Increased whole blood serotonin concentration in chronic schizophrenics. Arch Gen Psychiatry 1981: 38: 647-650.
7. COOPER SJ, KELLY CB, KING DJ. 5-hydroxyindoleacetic acid in cerebrospinal fluid and prediction of suicidal behavior in schizophrenia. Lancet 1992: 340: 940-941.
8. LARUELLE M, ABI-DARGHAM A, CASANOVA MF, TORI R, WEINBERGER DR, KLEINMAN JE. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia: a post-mortem study. Arch Gen Psychiatry 1993: 50: 810-818.
9. HSIAO JK, COLISON J, BARTHKO JJ et al. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. Arch Gen Psychiatry 1993: 50: 606-614.
10. OWEN RR, GUTIERREZ-ESTEINOU R, HSIAO J et al. Effects of clozapine and fluphenazine treatment on responses to m-chlorphenylpiperazine infusions in schizophrenia. Arch Gen Psychiatry 1993: 50: 636-644.
11. LIVINGSTON MG. Risperidone. Lancet 1994: 343: 457-460.
12. GOFF DC, BROTMAN AW, WAITES M, MCCORMICK S. Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 1990: 147: 492-494.
13. SYVÄLAHTI EKG, KALLIONIEMI H, LEHTO H. Citalopram in patients with unsatisfactory response to neuroleptics: an open follow-up study. Meth Find Exp Clin Pharmacol 1994: 16: 49-55.
14. VARTIAINEN H, TIIHONEN J. PUTKONEN A et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995: 91: 348-351.
15. SILVER H, NASSAR A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 1992: 31: 698-704.
16. GOFF DC, MIDHA KK, BROTMAN AW, WAITES M, BALDESSARINI RJ. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Am J Psychiatry 1991: 148: 790-792.
17. LOCK DJ, GWIRTSMAN HE, TARG EF. Possible adverse drug interactions between fluoxetine and other psychotropics. J Clin Psychopharmacol 1990: 10: 383-384.
18. AMES D, WIRSHING WC, MARDER SR, YUWILER A, BRAMMER GL. Fluoxetine in haloperidol-stabilized schizophrenics. The 146th Annual Meeting of the American Psychiatric Association, 22-27 May 1993, San Francisco. Program and Abstracts on New Research 76. Washington, DC: American Psychiatric Association, 1993.
19. FLEISHAKER JC, HULST LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994: 46: 35-39.
20. KOPONEN HJ, LEINONEN E, LEPOLA U. High serum trimipramine concentration during fluvoxamine treatment: a case report. Nord J Psychiatry 1994: 48: 333-335.
21. BRÖSEN K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Invest 1993: 71: 1002-1009.
22. VAN HARTEN J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993: 24: 203-220.
23. HYTTEL J. Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982: 6: 277-295.
24. BECH P, MALT UF, DENCKER SJ et al. Scales for assessment of diagnosis and severity of mental disorders. Acta Psychiatr Scand 1993: 87 (Suppl. 372): 30-31.
25. KAY SR. Positive and negative syndromes in schizophrenia. Assessment and research. New York: Brunner-Mazel, 1991.
26. KAY SR, OPLER LA, FISZBEIN A. Positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987: 13: 261-276.
27. DEROGATIS LR, MELISARATOS N. The brief symptom inventory: an introductory report. Psychol Med 1993: 13: 595-605.
28. BECH P, KASTRUP M, RAFAELSEN OJ. Mini-compendium of rating scales for states of anxiety, depression, mania and schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand 1986: 73 (Suppl. 326): 1-37.
29. LINGJAERDE O, AHLFORS UG, BECH P, DENCKER SJ, ELGEN K. The UKU side-effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side-effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987: 76 (Suppl. 334).
30. SIMPSON GM, ANGUS JWS. A rating scale for extra-pyramidal side-effects. Acta Psychiatr Scand 1979: 46 (Suppl. 212): 11-19.
31. SAS Institute Inc. SAS statistical software, version 6.08. Chicago: SAS Institute Inc., 1992.
32. MARDER SR, MEIBACH RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994: 151: 825-835.
33. BLAND JM, ALIMAN DG. Some examples of regression towards the mean. Br Med J 1994: 390: 780.
34. LAPORTE J-R, FIGUERAS A. Placebo effects in psychiatry. Lancet 1994: 344: 1206-1209.
35. TAIMINEN T, SYVÄLAHTI E, SAARIJÄRVI S et al. Prediction of positive placebo response among chronic schizophrenic out-patients. J Nerv Ment Dis 1996: 184: 109-113.
36. TATE JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxeline. Am J Psychiatry 1989: 146: 399-400.
37. CIRAULO DA, SHADER RI. Fluoxetine drug-drug interactions. I. Antidepressants and antipsychotics. J Clin Psychopharmacol 1990: 10: 48-50.
38. CASSADY S, THAKER GT. Addition of fluoxetine to clozapine. Am J Psychiatry 1992: 149: 1274.
39. KETAI R. Interaction between fluoxetine and neuroleptics. Am J Psychiatry 1993: 150: 836-837.
40. BALDESSARINI RJ, MARSH E. Fluoxetine and side-effects. Arch Gen Psychiatry 1990: 47: 191-192.
41. ARYA DK. Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatry 1994: 165: 728-733.